RxDoctor Payments Data

Allyson Bagenholm, MD

Family Medicine · Boca Raton, FLNPI 1023279916

Payments from drug & device makers

$347in general payments, 2019–2025

Across 12 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$118
  • Exact Sciences$97
  • Amgen$37
  • Pfizer$25
  • Lilly USA, LLC$23
  • Xeris Pharmaceuticals, Inc.$17
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$347 in reported general payments places this provider in the 40th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,000
Medicare patients
152
Services billed
1,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WegovySemaglutide51$67,143
OzempicSemaglutide29$24,954
Repatha SureclickEvolocumab39$23,947
MounjaroTirzepatide22$18,619
ElmironPentosan Polysulfate Sodium11$12,225
Repatha SyringeEvolocumab13$11,718
SynthroidLevothyroxine Sodium12$1,475
Rosuvastatin Calcium128$1,463
Levothyroxine Sodium48$726
ValacyclovirValacyclovir Hcl34$694
Escitalopram Oxalate18$659
Zolpidem Tartrate71$427
Clonazepam26$411
Amitriptyline Hcl14$388
Alprazolam39$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$18,61922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →